利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

14 条记录 (耗时 0.027 秒)

    Purinenucleoside derivative modified in 8-position and medical use thereof
    1.
    发明申请
    Purinenucleoside derivative modified in 8-position and medical use thereof 失效
    8位修饰的嘌呤核苷衍生物及其用途

    公开(公告)号：US20070179115A1

    公开(公告)日：2007-08-02

    申请号：US11717741

    申请日：2007-03-13

    申请人： Kazuya Tatani ,  Yoshinori Nonaka ,  Norihiko Kikuchi

    发明人： Kazuya Tatani ,  Yoshinori Nonaka ,  Norihiko Kikuchi

    IPC分类号： A61K31/7076 ,  C07H19/16

    CPC分类号： A61K45/06 ,  A61K31/7076 ,  C07H19/167 ,  C07H19/173

    摘要： The present invention provides an 8-modified purinenucleoside derivative which is useful for diseases associated with an abnormality of plasma uric acid level. An 8-modified purinenucleoside derivative represented by the following formula (I), a prodrug thereof or a pharmaceutically acceptable salt thereof, or a hydrate or solvate thereof, is useful for the prevention or treatment of gout, hyperuricemia, urinary lithiasis, hyperuricemic nephropathy or the like. In the formula, n is 1 or 2; RA is a hydrogen atom or a hydroxyl group; R1 is a hydrogen atom, a hydroxyl group, a thiol group, an amino group or a chlorine atom; ring J represents an optionally substituted 2-naphthyl group, or a group represented by the following general formula (II) wherein Y represents a single bond or a connecting group; ring Z represents an optionally substituted aryl group or heteroaryl group or the like; and R2 to R4, P1 and Q represents a halogen atom, a cyano group or the like.

    摘要翻译： 本发明提供了可用于与血浆尿酸水平异常相关的疾病的8-修饰的嘌呤核苷衍生物。 由下式（I）表示的8-修饰的嘌呤核苷衍生物，其前体药物或其药学上可接受的盐或其水合物或溶剂合物可用于预防或治疗痛风，高尿酸血症，尿结石病，高尿酸性肾病或 类似。 在该式中，n为1或2; R A是氢原子或羟基; R 1是氢原子，羟基，硫醇基，氨基或氯原子; 环J表示任选取代的2-萘基，或由以下通式（II）表示的基团，其中Y表示单键或连接基团; 环Z表示任选取代的芳基或杂芳基等; R 2〜R 4，P 1和Q表示卤素原子，氰基等。

    Benzimidazole derivatives and medical uses thereof
    2.
    发明授权
    Benzimidazole derivatives and medical uses thereof 失效
    苯并咪唑衍生物及其医疗用途

    公开(公告)号：US07547680B2

    公开(公告)日：2009-06-16

    申请号：US11473957

    申请日：2006-06-23

    申请人： Norihiko Kikuchi ,  Yoshinori Nonaka ,  Kazuya Tatani ,  Masahiro Hiratochi ,  Yu Kuramochi ,  Masayuki Isaji ,  Kazuo Shimizu ,  Takashi Miyagi

    发明人： Norihiko Kikuchi ,  Yoshinori Nonaka ,  Kazuya Tatani ,  Masahiro Hiratochi ,  Yu Kuramochi ,  Masayuki Isaji ,  Kazuo Shimizu ,  Takashi Miyagi

    IPC分类号： A01N43/04 ,  A61K31/70

    CPC分类号： C07H19/052

    摘要： The present invention provides benzimidazole derivatives represented by the following formula (I) or pharmaceutically acceptable salts thereof, or prodrugs thereof, which exert an inhibitory activity on sodium-dependent nucleoside transporter 2 and are useful for a disease associated with an abnormality of plasma uric acid level. The compounds of the present invention are useful for the prevention or treatment of gout, hyperuricemia, urinary lithiasis, hyperuricemic nephropathy or the like.In the formula, n is 1 or 2; R1 and R2 are H, a halogen atom, cyano group, optionally substituted alkyl group, optionally substituted aryl group or the like; R3 is H, a halogen atom, optionally substituted alkyl group or the like; R4 and R5 are H, a halogen atom, OH or the like; and R6 and RX are H or OH: RY is F or OH.

    摘要翻译： 本发明提供由下式（I）表示的苯并咪唑衍生物或其药学上可接受的盐或其前药，其对钠依赖性核苷转运蛋白2具有抑制活性，并且可用于与血浆尿酸异常有关的疾病 水平。 本发明的化合物可用于预防或治疗痛风，高尿酸血症，尿结石病，高尿酸性肾病等。 在该式中，n为1或2; R 1和R 2是H，卤素原子，氰基，任选取代的烷基，任选取代的芳基等; R3是H，卤素原子，任选取代的烷基等; R 4和R 5是H，卤素原子，OH等; R6和RX是H或OH：RY是F或OH。

    Purine nucleoside derivative modified in 8-position and medical use thereof
    3.
    发明授权
    Purine nucleoside derivative modified in 8-position and medical use thereof 失效
    8位修饰的嘌呤核苷衍生物及其用途

    公开(公告)号：US07795236B2

    公开(公告)日：2010-09-14

    申请号：US11717741

    申请日：2007-03-13

    申请人： Kazuya Tatani ,  Yoshinori Nonaka ,  Norihiko Kikuchi

    发明人： Kazuya Tatani ,  Yoshinori Nonaka ,  Norihiko Kikuchi

    IPC分类号： A01N43/04 ,  A61K31/70 ,  C07H19/00 ,  C07H19/16

    CPC分类号： A61K45/06 ,  A61K31/7076 ,  C07H19/167 ,  C07H19/173

    摘要： The present invention provides an 8-modified purinenucleoside derivative which is useful for diseases associated with an abnormality of plasma uric acid level. An 8-modified purinenucleoside derivative represented by the following formula (I), a prodrug thereof or a pharmaceutically acceptable salt thereof, or a hydrate or solvate thereof, is useful for the prevention or treatment of gout, hyperuricemia, urinary lithiasis, hyperuricemic nephropathy or the like.In the formula, n is 1 or 2; RA is a hydrogen atom or a hydroxyl group; R1 is a hydrogen atom, a hydroxyl group, a thiol group, an amino group or a chlorine atom; ring J represents an optionally substituted 2-naphthyl group, or a group represented by the following general formula (II) wherein Y represents a single bond or a connecting group; ring Z represents an optionally substituted aryl group or heteroaryl group or the like; and R2 to R4, P1 and Q represents a halogen atom, a cyano group or the like.

    摘要翻译： 本发明提供了可用于与血浆尿酸水平异常相关的疾病的8-修饰的嘌呤核苷衍生物。 由下式（I）表示的8-修饰的嘌呤核苷衍生物，其前体药物或其药学上可接受的盐或其水合物或溶剂合物可用于预防或治疗痛风，高尿酸血症，尿结石病，高尿酸性肾病或 类似。 在该式中，n为1或2; RA是氢原子或羟基; R1是氢原子，羟基，硫醇基，氨基或氯原子; 环J表示任选取代的2-萘基，或由以下通式（II）表示的基团，其中Y表示单键或连接基团; 环Z表示任选取代的芳基或杂芳基等; R2和R4，P1和Q表示卤原子，氰基等。

    PURINE NUCLEOSIDE DERIVATIVE MODIFIED IN 8-POSITION AND MEDICAL USE THEREOF
    4.
    发明申请
    PURINE NUCLEOSIDE DERIVATIVE MODIFIED IN 8-POSITION AND MEDICAL USE THEREOF 失效
    嘌呤核苷衍生物8位置修饰及其医疗用途

    公开(公告)号：US20100249054A9

    公开(公告)日：2010-09-30

    申请号：US11717741

    申请日：2007-03-13

    申请人： Kazuya Tatani ,  Yoshinori Nonaka ,  Norihiko Kikuchi

    发明人： Kazuya Tatani ,  Yoshinori Nonaka ,  Norihiko Kikuchi

    IPC分类号： A61K31/7076 ,  C07H19/16

    CPC分类号： A61K45/06 ,  A61K31/7076 ,  C07H19/167 ,  C07H19/173

    摘要： The present invention provides an 8-modified purinenucleoside derivative which is useful for diseases associated with an abnormality of plasma uric acid level. An 8-modified purinenucleoside derivative represented by the following formula (I), a prodrug thereof or a pharmaceutically acceptable salt thereof, or a hydrate or solvate thereof, is useful for the prevention or treatment of gout, hyperuricemia, urinary lithiasis, hyperuricemic nephropathy or the like. In the formula, n is 1 or 2; RA is a hydrogen atom or a hydroxyl group; R1 is a hydrogen atom, a hydroxyl group, a thiol group, an amino group or a chlorine atom; ring J represents an optionally substituted 2-naphthyl group, or a group represented by the following general formula (II) wherein Y represents a single bond or a connecting group; ring Z represents an optionally substituted aryl group or heteroaryl group or the like; and R2 to R4, P1 and Q represents a halogen atom, a cyano group or the like.

    摘要翻译： 本发明提供了可用于与血浆尿酸水平异常相关的疾病的8-修饰的嘌呤核苷衍生物。 由下式（I）表示的8-修饰的嘌呤核苷衍生物，其前体药物或其药学上可接受的盐或其水合物或溶剂合物可用于预防或治疗痛风，高尿酸血症，尿结石病，高尿酸性肾病或 类似。 在该式中，n为1或2; RA是氢原子或羟基; R1是氢原子，羟基，硫醇基，氨基或氯原子; 环J表示任选取代的2-萘基，或由以下通式（II）表示的基团，其中Y表示单键或连接基团; 环Z表示任选取代的芳基或杂芳基等; R2和R4，P1和Q表示卤原子，氰基等。

    Bolted joint structure
    6.
    发明授权
    Bolted joint structure 有权
    螺栓接头结构

    公开(公告)号：US09157462B2

    公开(公告)日：2015-10-13

    申请号：US13879886

    申请日：2011-10-12

    申请人： Yoshinori Nonaka ,  Masahiro Kashiwagi ,  Toshio Abe

    发明人： Yoshinori Nonaka ,  Masahiro Kashiwagi ,  Toshio Abe

    IPC分类号： F16B5/02 ,  F16B31/06 ,  B64C1/06

    CPC分类号： F16B5/02 ,  B64C1/06 ,  F16B31/06 ,  Y10T403/74

    摘要： Joint parts of joinable plates to be joined to each other are joined by a plurality of joining bolts. The joining bolts are arranged in a direction of a tensile load F. The joint parts of the plate members have four sections T1 to T4 that vary in elastic modulus. The elastic modulus (E1 to E4) of these sections T1 to T4 have a relationship of E1(T1)>E2(T2)>E3(T3)>E4(T4).

    摘要翻译： 要接合的连接板的接合部分通过多个接合螺栓连接。 接合螺栓沿拉伸载荷F的方向布置。板构件的接合部具有弹性模量变化的四个部分T1〜T4。 这些部分T1至T4的弹性模量（E1至E4）具有E1（T1）> E2（T2）> E3（T3）> E4（T4）的关系。

    Polyphenylene ether resin
    8.
    发明授权
    Polyphenylene ether resin 失效
    聚苯醚树脂

    公开(公告)号：US5861437A

    公开(公告)日：1999-01-19

    申请号：US930433

    申请日：1997-10-07

    申请人： Hiromu Harada ,  Yukihiko Hotei ,  Hideki Hujikura ,  Yoshinori Nonaka ,  Koji Kamata ,  Mitsuhiro Ichihara ,  Hiroshi Kusama ,  Humiyasu Satoh

    发明人： Hiromu Harada ,  Yukihiko Hotei ,  Hideki Hujikura ,  Yoshinori Nonaka ,  Koji Kamata ,  Mitsuhiro Ichihara ,  Hiroshi Kusama ,  Humiyasu Satoh

    IPC分类号： C08G65/48 ,  C08L71/12 ,  A61K31/785

    CPC分类号： C08L71/126 ,  C08G65/485

    摘要： A poly(phenylene ether) resin composed of structural units represented by the general formula: ##STR1## (wherein R.sup.1, R.sup.2 and R.sup.3 represent each alkyl, cycloalkyl, etc. or H (provided that two or more of R.sup.1, R.sup.2 and R.sup.3 do not represent H at the same time), or one of R.sup.1, R.sup.2 and R.sup.3 represents alkyl or H while the others together form a saturated ring, or R.sup.1, R.sup.2 and R.sup.3 together form an aromatic ring; A represents alkyl; p is an integer of from 3 to 5; and Y.sup.- represents a pharmaceutically acceptable acid residue) and/or structural units represented by the general formula: ##STR2## (wherein R.sup.4, R.sup.5 and R.sup.6 represents each alkyl, cycloalkyl, etc. or H (provided that two or more of R.sup.4, R.sup.5 and R.sup.6 do not represent H at the same time), or one of R.sup.4, R.sup.5 and R.sup.6 represents alkyl or H while the others together form a saturated ring, or R.sup.4, R.sup.5 and R.sup.6 together form an aromatic ring; and A, p and Y.sup.- have same meanings as defined above) and structural units represented by the general formula: ##STR3## (wherein R.sup.7 and R.sup.8 represents each alkyl, cycloalkyl, etc. or together form a saturated ring; q is an integer of from 3 to 20; and A, p, and Y.sup.- have same meanings as defined above) wherein the sum of the contents of the structural units represented by the general formula (I) and the structural units represented by the general formula (II) amounts to 40 to 96% by mole and the content of the structural units represented by the general formula (III) amounts to 4 to 60% by mole based upon the content of phenylene ether component and a process for producing the same. The poly(phenylene ether) resins have the effect of adsorbing bile acids and are useful as a cholesterol reducing agent.

    摘要翻译： PCT No.PCT / JP96 / 00931 Sec。 371日期1997年10月7日第 102（e）日期1997年10月7日PCT提交1996年4月5日PCT公布。 公开号WO96 / 32435 日期：1996年10月17日由以下通式表示的结构单元构成的聚苯醚树脂：烷基，环烷基等或H（前提是R1，R2和R3中的两个或更多个不表示相同的H 时间），或者R1，R2和R3中的一个表示烷基或H，而另一个一起形成饱和环，​​或者R1，R2和R3一起形成芳香环; A代表烷基; p是3至5的整数; 和/或由以下通式表示的结构单元：其中R 4，R 5和R 6表示各自的烷基，环烷基等或H（条件是两个或多个 R4，R5和R6不同时表示H），或者R4，R5和R6中的一个表示烷基或H，而另一个共同形成饱和环，​​或者R4，R5和R6一起形成芳香环; A，p和Y-具有与上述相同的含义）和由通式（III）表示的结构单元（其中R 7和R 8表示各个烷基，环烷基等或一起形成饱和环; q为 3〜20的整数，A，p，Y-具有与上述相同的含义），其中由通式（I）表示的结构单元的含量和由通式 （II）表示的结构单元的含量为40〜96摩尔％，通式（I）表示的结构单元的含量 II）相对于亚苯基醚成分的含量为4〜60摩尔％及其制造方法。 聚苯醚树脂具有吸附胆汁酸的作用，可用作胆固醇降低剂。